Fundraising FoxBone Biologics
NASDAQ: BBLGBoston, US · Delaware corporation · 1 known investors
Find your way into Bone Biologics
12 people in our graph can introduce you to the Bone Biologics team.
Sign up to see every warm intro you have to Bone Biologics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Bone Biologics team. We find them
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Bone Biologics develops a medical device combining a recombinant human protein called NELL-1 with demineralized bone matrix for use in spinal fusion and other orthopedic procedures to promote controlled bone regeneration. The company is conducting clinical trials of its lead product candidate, NB1, in lumbar spinal fusion applications and is pursuing FDA approval before commercialization in the United States.
Founders & leadership
SL
Steve La NeveExecutive
JF
Jeffrey FrelickChief Executive Officer and President
DH
Deina H. WalshChief Financial OfficerDeina H. Walsh is Chief Financial Officer of Bone Biologics, where she oversees accounting operations and provides strategic financial guidance to senior management. She has extensive experience in financial leadership, GAAP reporting, internal controls, and accounting systems across public and private sector organizations.
CS
Chia SooNamed on SEC filing
BW
Benjamin WuNamed on SEC filing
Board
BS
Bruce StroeverBoard director
JD
Jimmy DelshadBoard director
WC
William CoffinBoard director
JB
John BoothBoard director
Investors · 1
Hankey Capitalreported
How we know: the S-1 prospectus · funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$8.5M disclosed across 3 of 5 rounds · 2016–2026
▶$729KraisedNov 2023 · 4 investors · BiotechnologyRule 506(b)
▶$729KraisedNov 2023 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Don R. HankeyDirector
- Deina H. WalshExecutive Officer
- Siddhesh AngleDirector
- Bruce StroeverDirector
- Erick LuceraDirector
- Jeffrey FrelickExecutive Officer
- Offering amount
- $729K
- Amount sold
- $729K
- Sales commissions
- $51K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Nov 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.9MraisedJul 2018 · 4 investors · BiotechnologyRule 506(b)
▶$5.9MraisedJul 2018 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Deina WalshExecutive Officer
- Stephen R LaNeveExecutive Officer, Director
- Don HankeyDirector
- Bret HankeyDirector
- Jimmy DelshadDirector
- Bruce StroeverDirector
- John BoothDirector
- Jeff FrelickExecutive Officer
- Offering amount
- $5.9M
- Amount sold
- $5.9M
- First sale
- Jul 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.9MraisedMar 2018 · 2 investors · BiotechnologyRule 506(b)
▶$1.9MraisedMar 2018 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Stephen R LaNeveExecutive Officer, Director
- DEINA WALSHExecutive Officer
- BRET HANKEYDirector
- JEFFREY FRELICKExecutive Officer
- JIMMY DELSHADDirector
- BRUCE STROEVERDirector
- JOHN BOOTHDirector
- Offering amount
- $10M
- Amount sold
- $1.9M
- First sale
- Aug 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4.5MofferedMar 2016 · 3 investors · BiotechnologyRule 506(b)
▶$4.5MofferedMar 2016 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Chia SooDirector
- Benjamin WuDirector
- Jimmy DelshadDirector
- William CoffinDirector
- Bruce StroeverDirector
- Jeff FrelickExecutive Officer
- Deina WalshExecutive Officer
- Steve La NeveExecutive Officer
- John BoothDirector
- Offering amount
- $4.5M
- First sale
- Feb 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Bone Biologics do?
- Bone Biologics develops a medical device combining a recombinant human protein called NELL-1 with demineralized bone matrix for use in spinal fusion and other orthopedic procedures to promote controlled bone regeneration. The company is conducting clinical trials of its lead product candidate, NB1, in lumbar spinal fusion applications and is pursuing FDA approval before commercialization in the United States.
- Who are Bone Biologics's investors?
- Bone Biologics's investors include Hankey Capital.
- How much funding has Bone Biologics raised?
- Bone Biologics has disclosed $8.5M raised across 3 of its 5 known rounds.
- Where is Bone Biologics headquartered?
- Bone Biologics is headquartered in Boston, US.